Univision Updates Finances in Most Recent IPO Filing
Univision Holdings has amended its filing with U.S. the Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Univision Holdings has amended its filing with U.S. the Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Facebook CEO Mark Zuckerberg has answered critics of Free Basics, a free, limited version of the Internet for people who cannot afford a broadband subscription or a smartphone data plan.
Valeant Pharmaceuticals watched its shares move lower in Monday’s trading session on a health scare from one of its top executives.
Continuing to pump more oil while prices show no signs of stopping their slide has led the Kingdom of Saudi Arabia to a budget deficit of $97.9 billion in 2015.
An announcement right before Christmas from Air Lease signaled that the air leasing outfit was selling 25 ATR aircraft in its fleet to Nordic Aviation Capital.
While these stocks are only suitable for very aggressive risk tolerant accounts, the anticipated increase in spending in 2016 could make a solid difference to the top and bottom lines of these well-run companies.
Argus reiterated Nike's Buy rating and raised its price target to $77.00, almost $5.00 higher than the consensus analyst price target.
More than a year ago, Airbus announced that it would collaborate with Aerion, a start-up with plans to build a supersonic business jet, the AS2.
Chimerix absolutely led the bears in Monday’s trading session on less-than-favorable results from a late-stage trial.
AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Audi, one of the luxury divisions of Volkswagen, along with Porsche, will cut spending, most likely as a means to help VW keep its cash war chest in light of legal costs from its…
For online retailers and furniture retailers, the 2015 holiday shopping season was a big winner. E-commerce sales rose 20% year over year.
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and growth next year.
While there is certainly no guarantee that any of these hot biotech companies is bought, they each offer aggressive accounts big potential upside and have unique products and clinical possibilities going forward.
The short interest data have been released for the December 15 settlement date, and short interest for the selected stocks was saw a definite jump.